🇺🇸 FDA
Patent

US 7662619

Sol-fusin: use of GP64-6His to catalyze membrane fusion

granted A61KA61K9/127

Quick answer

US patent 7662619 (Sol-fusin: use of GP64-6His to catalyze membrane fusion) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Feb 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Feb 16 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K9/127